×
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
NASDAQ:ACRS

Aclaris Therapeutics Stock Forecast, Price & News

$14.36
+0.30 (+2.13%)
(As of 06/29/2022 12:00 AM ET)
Add
Compare
Today's Range
$13.84
$14.60
50-Day Range
$10.16
$15.99
52-Week Range
$9.26
$19.97
Volume
395,178 shs
Average Volume
486,063 shs
Market Capitalization
$956.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.00
30 days | 90 days | 365 days | Advanced Chart

Receive ACRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACRS Stock Forecast (MarketRank)

Overall MarketRank

2.23 out of 5 stars

Medical Sector

352nd out of 1,432 stocks

Pharmaceutical Preparations Industry

151st out of 685 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
Aclaris Therapeutics logo

About Aclaris Therapeutics (NASDAQ:ACRS)

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

ACRS Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACRS
Employees
72
Year Founded
N/A

Company Calendar

Last Earnings
5/10/2022
Today
6/29/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$36.00
High Stock Price Forecast
$50.00
Low Stock Price Forecast
$26.00
Forecasted Upside/Downside
+150.7%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
5 Analysts

Profitability

Net Income
$-90.86 million
Net Margins
-1,256.80%
Pretax Margin
-1,256.80%

Debt

Sales & Book Value

Annual Sales
$6.76 million
Book Value
$3.22 per share

Miscellaneous

Free Float
61,122,000
Market Cap
$956.12 million
Optionable
Optionable
Beta
0.67














Aclaris Therapeutics Frequently Asked Questions

Should I buy or sell Aclaris Therapeutics stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Aclaris Therapeutics stock.
View analyst ratings for Aclaris Therapeutics
or view top-rated stocks.

What is Aclaris Therapeutics' stock price forecast for 2022?

5 Wall Street research analysts have issued 1 year price objectives for Aclaris Therapeutics' shares. Their ACRS stock forecasts range from $26.00 to $50.00. On average, they anticipate Aclaris Therapeutics' share price to reach $36.00 in the next year. This suggests a possible upside of 150.7% from the stock's current price.
View analysts' price targets for Aclaris Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Aclaris Therapeutics' stock price performed in 2022?

Aclaris Therapeutics' stock was trading at $14.54 on January 1st, 2022. Since then, ACRS shares have decreased by 1.2% and is now trading at $14.36.
View the best growth stocks for 2022 here
.

When is Aclaris Therapeutics' next earnings date?

Aclaris Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Aclaris Therapeutics
.

How were Aclaris Therapeutics' earnings last quarter?

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) posted its quarterly earnings data on Tuesday, May, 10th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.08. The biotechnology company earned $1.45 million during the quarter, compared to the consensus estimate of $1.67 million. Aclaris Therapeutics had a negative net margin of 1,256.80% and a negative trailing twelve-month return on equity of 39.08%. The firm's revenue for the quarter was down 18.2% on a year-over-year basis.
View Aclaris Therapeutics' earnings history
.

Who are Aclaris Therapeutics' key executives?

Aclaris Therapeutics' management team includes the following people:

What is Neal Walker's approval rating as Aclaris Therapeutics' CEO?

1 employees have rated Aclaris Therapeutics CEO Neal Walker on Glassdoor.com. Neal Walker has an approval rating of 100% among Aclaris Therapeutics' employees. This puts Neal Walker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Aclaris Therapeutics own?

What is Aclaris Therapeutics' stock symbol?

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

Who are Aclaris Therapeutics' major shareholders?

Aclaris Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (9.35%), BlackRock Inc. (6.51%), Rock Springs Capital Management LP (5.81%), Vanguard Group Inc. (4.45%), RA Capital Management L.P. (2.73%) and Renaissance Technologies LLC (2.38%). Company insiders that own Aclaris Therapeutics stock include Andrew N Schiff, David N Gordon, Frank Ruffo, Joseph Monahan, Kamil Ali-Jackson and Neal Walker.
View institutional ownership trends for Aclaris Therapeutics
.

Which major investors are selling Aclaris Therapeutics stock?

ACRS stock was sold by a variety of institutional investors in the last quarter, including Parkman Healthcare Partners LLC, Affinity Asset Advisors LLC, Renaissance Technologies LLC, Ghost Tree Capital LLC, BlackRock Inc., UBS Group AG, Bank of America Corp DE, and Northern Trust Corp. Company insiders that have sold Aclaris Therapeutics company stock in the last two years include Andrew N Schiff, David N Gordon, Frank Ruffo, Joseph Monahan, Kamil Ali-Jackson, and Neal Walker.
View insider buying and selling activity for Aclaris Therapeutics
or view top insider-selling stocks.

Which major investors are buying Aclaris Therapeutics stock?

ACRS stock was acquired by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Assenagon Asset Management S.A., Frazier Life Sciences Management L.P., Wellington Management Group LLP, Great Point Partners LLC, Verition Fund Management LLC, Verition Fund Management LLC, and Integral Health Asset Management LLC.
View insider buying and selling activity for Aclaris Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Aclaris Therapeutics?

Shares of ACRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aclaris Therapeutics' stock price today?

One share of ACRS stock can currently be purchased for approximately $14.36.

How much money does Aclaris Therapeutics make?

Aclaris Therapeutics (NASDAQ:ACRS) has a market capitalization of $956.12 million and generates $6.76 million in revenue each year. The biotechnology company earns $-90.86 million in net income (profit) each year or ($1.370010) on an earnings per share basis.

How many employees does Aclaris Therapeutics have?

Aclaris Therapeutics employs 72 workers across the globe.

How can I contact Aclaris Therapeutics?

Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The official website for Aclaris Therapeutics is www.aclaristx.com. The biotechnology company can be reached via phone at (484) 324-7933, via email at [email protected], or via fax at 484-320-2344.

This page (NASDAQ:ACRS) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.